Los Angeles Capital Management
LFCR icon

Los Angeles Capital Management’s Lifecore Biomedical LFCR Stock Holding History

Los Angeles Capital Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-26,520
Closed -$298K – 1541
2021
Q2 		$298K Sell
26,520
-14,191
-35% -$164K ﹤0.01% 1390
2021
Q1 		$432K Buy
40,711
+670
+2% +$7.53K ﹤0.01% 1278
2020
Q4 		$434K Sell
40,041
-9,130
-19% -$94.3K ﹤0.01% 1260
2020
Q3 		$478K Sell
49,171
-21,368
-30% -$204K ﹤0.01% 1096
2020
Q2 		$561K Buy
+70,539
New +$728K ﹤0.01% 1067

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Los Angeles Capital Management's LFCR Position: Q3 2021 in Review

Los Angeles Capital Management sold out of Lifecore Biomedical (LFCR) in Q3 2021, closing a stake of 26,520 shares — an estimated $298K sold.

Los Angeles Capital Management first reported a position in LFCR in Q2 2020 and held it in 5 quarters. The position peaked at $561K in Q2 2020. 92 funds tracked by Wall St. Rank hold LFCR as of Q3 2021.

  • Los Angeles Capital Management reported no remaining Lifecore Biomedical position as of Q3 2021 after selling out during the quarter.
  • Los Angeles Capital Management sold 26,520 Lifecore Biomedical shares in Q3 2021, an estimated $298K.
  • Los Angeles Capital Management first reported a position in Lifecore Biomedical in Q2 2020 and held it in 5 quarters.
  • Los Angeles Capital Management's Lifecore Biomedical position peaked at $561K in Q2 2020.
  • 92 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2021.

Based on Los Angeles Capital Management's 13F filing for Q3 2021, filed 5 Nov 2021.